Dubow Adam 4

What Happened
Adam Dubow, General Counsel & Secretary of Day One Biopharmaceuticals (DAWN), received two equity awards on 2026-01-30: a grant of 105,000 derivative awards (stock options) and a grant of 70,000 Restricted Stock Units (RSUs). Both grants are reported with a $0.00 acquisition price (typical for compensation awards); no shares were sold. These are compensation/retention awards rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-01-30; reported to the SEC the same day (timely filing).
• 105,000 derivative awards (options) reported at $0.00; vesting: 1/48th monthly beginning Feb 28, 2026 (4‑year monthly schedule). (Footnote F1)
• 70,000 RSUs reported at $0.00; each RSU converts to one share at settlement; vesting: 1/16th quarterly on Feb 15, May 15, Aug 15 and Nov 15 (4‑year quarterly schedule). (Footnotes F2–F4)
• RSUs do not expire; they either vest or are canceled prior to vesting (F4).
• Shares owned after the transaction are not specified in the provided filing excerpt.

Context

• The 105,000 derivative award appears to be stock options (right to buy shares per vest schedule); the 70,000 RSUs are a contingent right to receive shares when they vest and settle. Neither award conveys immediately tradable stock or immediate cash proceeds.
• Such grants are commonly part of executive compensation and retention packages and do not by themselves indicate buying or selling intent in the open market.